This company develops a modular platform for the on-demand self-assembly of smart, multifunctional nanobiomaterials. Guided by a One Health approach, they are building business units focused on disease detection, prevention, and treatment. Their proprietary technology leverages expertise in protein engineering, immunology, and vaccinology to address global health challenges.
Funding
$250K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SFounders
Product
Problem
Current methods for developing nanobiodevices and nanobiomaterials often lack modularity and cost-effectiveness, hindering rapid innovation and adaptation for diverse applications in disease detection, prevention, and treatment. Traditional approaches struggle to achieve precise control over the self-assembly of viral proteins, limiting the creation of multifunctional nanostructures.
Solution
Eureka Nanobioengineering offers a modular and cost-effective platform for the on-demand self-assembly of smart, multifunctional nanobiomaterials. Through rational protein design and engineering, the platform achieves full control of the self-assembly mechanism of multiple viral proteins, triggering oligomerization into homogeneous, reproducible, and monodisperse particles. These proteins serve as scaffolds that can be fused to cargoes of different functionalities, enabling combinatorial design and the creation of soluble, stable, multivalent, and multicomponent particles. The platform facilitates the development of next-generation vaccines, in vitro diagnostics, and solutions for personalized medicine under the "One Health" approach.
Target Audience
The primary target audience includes researchers and companies in the fields of personalized medicine, vaccine development, and diagnostics seeking a versatile platform for creating advanced nanobiodevices and nanobiomaterials.
Features
- Rational protein design and engineering for controlled self-assembly of viral proteins.
- Modular platform enabling on-demand integration of diverse functionalities.
- Generation of homogeneous, reproducible, and monodisperse nanoparticles.
- Topologically optimized cargo display for maximized function through controlled cargo orientation.
- Preclinical proof of concept demonstrating safe and robust immune responses.
- Facile conjugation with antibodies and minibinders for multivalent analyte detection.
- Capability for multiplex, quantitative fluorescent detection.